MedTrace Logo

Vasoreactivity in Carriers of Genetic Polymorphisms

NCT00160888 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2005-09-12

No results posted yet for this study

Summary

The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.

Conditions

  • Healthy

Interventions

DRUG

sodium nitroprusside, bradykinin, acetylcholine

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Walter E Haefeli, MD · Dept. of Internal Medicine VI, University of Heidelberg

Study Design

Allocation
NON_RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-11-30
Completion
2006-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160888 on ClinicalTrials.gov